BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 11318113)

  • 1. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death.
    Liu CS; Kong B; Xia HH; Ellem KA; Wei MQ
    J Gene Med; 2001; 3(2):145-52. PubMed ID: 11318113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following non-viral transfection.
    Sheridan PJ; Lawrie A; Crossman DC; Holt CM; Newman CM
    J Gene Med; 2005 Mar; 7(3):375-85. PubMed ID: 15543525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
    Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
    J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo].
    Kong BH; Wang WX; Liu CS; Ma DX; Qu X
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):195-8. PubMed ID: 12885362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
    Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
    Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bystander effect mediated by herpes simplex virus-thymidine kinase/ganciclovir approach on prostatic cancer cells and its regulation].
    Xing Y; Lu G; Xiao Y; Zeng F; Zhang Q; Xiong P; Feng W
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1484-7. PubMed ID: 12509912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
    Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
    Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bicistronic lentiviral vector-mediated herpes simplex virus thymidine kinase/ganciclovir system on human lens epithelial cells.
    Yang J; Liu TJ; Lu Y
    Curr Eye Res; 2007 Jan; 32(1):33-42. PubMed ID: 17364733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells.
    Rubsam LZ; Boucher PD; Murphy PJ; KuKuruga M; Shewach DS
    Cancer Res; 1999 Feb; 59(3):669-75. PubMed ID: 9973216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase.
    Roy V; Qiao J; de Campos-Lima P; Caruso M
    Gene Ther; 2005 Jan; 12(2):169-76. PubMed ID: 15483667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV(1)-TK/GCV) system as an effective "in vivo death switch" of live tumor vaccines].
    Kang Y; Xu CJ; Liu XS; Wu CQ; Zhong CP; Gu JR
    Ai Zheng; 2005 Aug; 24(8):909-14. PubMed ID: 16086864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea.
    Boucher PD; Ostruszka LJ; Shewach DS
    Cancer Res; 2000 Mar; 60(6):1631-6. PubMed ID: 10749133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction of a plasmid vector of fused protein genes driven by human insulin-like growth factor II P3 promoter].
    Zhou HK; Yang DH; Tang SH; Huang W; Lu XH
    Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(2):106-10. PubMed ID: 16620715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of adenovirus-mediated TK/GCV gene therapy in combination with TNF-alpha against murine bladder cancer cells in vitro].
    Shi XH; Tan WL; Zhu WH; Liang ZK; DU YJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):750-3. PubMed ID: 18504196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Killing effects of ganciclovir on human pulmonary adenocarcinoma cell A549 transduced with HSV1-TK gene in vitro and in vivo.
    He XL; Guo XJ; Qian GS; He XH; Huang GJ; Chen WZ; Li SP
    Acta Pharmacol Sin; 2001 Oct; 22(10):901-6. PubMed ID: 11749772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.
    Mathis JM; Williams BJ; Sibley DA; Carroll JL; Li J; Odaka Y; Barlow S; Nathan CO; Li BD; DeBenedetti A
    J Gene Med; 2006 Sep; 8(9):1105-20. PubMed ID: 16802401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene.
    Yang L; Hwang R; Chiang Y; Gordon EM; Anderson WF; Parekh D
    Clin Cancer Res; 1998 Mar; 4(3):731-41. PubMed ID: 9533543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.
    Rivas C; Miller AR; Collado M; Lam EW; Apperley JF; Melo JV
    Mol Ther; 2001 May; 3(5 Pt 1):642-52. PubMed ID: 11356068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of HIV-1 TAT peptide as an enhancer of HSV-TK/GCV cancer gene therapy.
    Rautsi O; Lehmusvaara S; Ketola A; Määttä AM; Wahlfors J; Pellinen R
    Cancer Gene Ther; 2008 May; 15(5):303-14. PubMed ID: 18309353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
    Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.